Condition: β -Thalassemia · Sponsor: Kind Pharmaceuticals LLC
This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.
This description comes directly from the study's public registry record.
Yusha Zhu, MD, PhD · 6467252552 · yushazhu@kindpharmaceutical.com
Always discuss trial participation with your own doctor first.
| Nanfang Hospital Southern Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Maoming People's Hospital | Maoming, Guangdong, China | Recruiting |
| Liuzhou People's Hospital | Liuzhou, Guangxi, China | Recruiting |
| Guangxi Medical University No.1 Affiliated Hospital | Nanning, Guangxi, China | Recruiting |
| Hainan General Hospital | Haikou, Hainan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06302491